Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2015
Price : $35 *
At a glance
- Drugs Aflibercept/rinucumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Regeneron Pharmaceuticals
- 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 11 Mar 2014 New trial record